Regado Biosciences
Executives
7Board of Directors
4Regado Biosciences Board of Directors
4 Board of directors
Regado Biosciences has 4 board of directors, including Dennis Podlesak.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
Dennis Podlesak | Regado Biosciences | ||
Jeff Clark | Jeff is a serial entrepreneur and venture capitalist based in RTP, NC. He brings strategic planning and operational experience to early stage companies to create an effective business culture, build a dynamic Board of Directors, investor base and leadership team, and develop strategic partnerships both in the local community and with national and international companies. Jeff co-founded Veritas Collaborative in Durham, NC (a specialty hospital system for the treatment of eating disorders) with Stacie McEntyre and Chase Bannister in 2010 and served as Chair of the Board of Managers thru 2019. Jeff co-founded Cellarian in Houston (a company offering integrated treatment programs for chronic pain and chemical dependency) with Michael Sprintz and Richard Holcomb in 2016 and serves as co-Chair of the Board of Directors. Jeff co-founded Essential Health (a new company advancing personalized medicine) with Corey DeHaven and Jay Stevens in 2016 and served as Chair of the Board of Directors thru Q320. Jeff also co-founded Matchwell (an online job marketplace that’s changing the way healthcare professionals and organizations come together for work) with Rob Crowe and Suzanne Masino in 2017 and serves as Board Chair. Jeff founded Aurora Funds in 1994 with Scott Albert and serves as Managing Partner. Aurora raised five early-stage venture funds with total AUM exceeding $250 million. Jeff led the Life Science team and has overseen investments in more than 30 companies and has full cycle investing experience from inception to exit including numerous IPO’s and M&A transactions. He has served on public and private boards of over 15 different Aurora portfolio companies including: Argos (ARGS – Nasdaq), Cardioxyl (sold to Bristol Myers), Regado, (RGDO – Nasdaq), Valor (sold to Humana), Hyperbranch (sold to Stryker) and currently serves as an observer for the board of Metabolon. He maintains strong ties to the RTP community, serving on visiting boards at local Universities and on the boards of regional entrepreneurial organizations and not-for-profits. His service includes past Board Chair for NC's CED, and the Board of Directors for TROSA where he is past Chairman (2 years) and past member of the Executive Committee (16 years). | Regado Biosciences | |
Jesse Treu | Jesse has been a partner of Domain since its inception in 1985. He has been a director of 38 early-stage healthcare companies, 23 of which have so far become successful public companies. Present board memberships include Afferent Pharmaceuticals, Aldeyra Pharmaceuticals, Sebacia, Tandem Diabetes Care, Veracyte and Xagenic. He has served as a founder, president and chairman of numerous venture stage companies. Prior to the formation of Domain, Jesse was vice president of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as president and CEO of Microsonics, a pioneer in computer image processing for cardiology. Previous to that, Jesse held executive positions at Technicon Instruments Corporation (now Siemens Medical Solutions Diagnostics) and at GE. He received his B.S. in physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University. | Regado Biosciences | |
Sherrill Neff | Quaker Partners manages venture capital and growth equity investments, with > $700 million-in-assets under management. Based in Philadelphia, PA. Quaker Partners has invested only in healthcare companies, primarily in the Mid-Atlantic Region. Sectors: Biopharmaceuticals, Medical Technology and Medical Devices, Clinical Diagnostics and Life Science Tools, Healthcare Services. Our funds are fully committed, and we are not making new investments at this time. | Regado Biosciences |
Name | Dennis Podlesak | Jeff Clark | Jesse Treu | Sherrill Neff |
|---|---|---|---|---|
Firm | ||||
Work History | Jeff is a serial entrepreneur and venture capitalist based in RTP, NC. He brings strategic planning and operational experience to early stage companies to create an effective business culture, build a dynamic Board of Directors, investor base and leadership team, and develop strategic partnerships both in the local community and with national and international companies. Jeff co-founded Veritas Collaborative in Durham, NC (a specialty hospital system for the treatment of eating disorders) with Stacie McEntyre and Chase Bannister in 2010 and served as Chair of the Board of Managers thru 2019. Jeff co-founded Cellarian in Houston (a company offering integrated treatment programs for chronic pain and chemical dependency) with Michael Sprintz and Richard Holcomb in 2016 and serves as co-Chair of the Board of Directors. Jeff co-founded Essential Health (a new company advancing personalized medicine) with Corey DeHaven and Jay Stevens in 2016 and served as Chair of the Board of Directors thru Q320. Jeff also co-founded Matchwell (an online job marketplace that’s changing the way healthcare professionals and organizations come together for work) with Rob Crowe and Suzanne Masino in 2017 and serves as Board Chair. Jeff founded Aurora Funds in 1994 with Scott Albert and serves as Managing Partner. Aurora raised five early-stage venture funds with total AUM exceeding $250 million. Jeff led the Life Science team and has overseen investments in more than 30 companies and has full cycle investing experience from inception to exit including numerous IPO’s and M&A transactions. He has served on public and private boards of over 15 different Aurora portfolio companies including: Argos (ARGS – Nasdaq), Cardioxyl (sold to Bristol Myers), Regado, (RGDO – Nasdaq), Valor (sold to Humana), Hyperbranch (sold to Stryker) and currently serves as an observer for the board of Metabolon. He maintains strong ties to the RTP community, serving on visiting boards at local Universities and on the boards of regional entrepreneurial organizations and not-for-profits. His service includes past Board Chair for NC's CED, and the Board of Directors for TROSA where he is past Chairman (2 years) and past member of the Executive Committee (16 years). | Jesse has been a partner of Domain since its inception in 1985. He has been a director of 38 early-stage healthcare companies, 23 of which have so far become successful public companies. Present board memberships include Afferent Pharmaceuticals, Aldeyra Pharmaceuticals, Sebacia, Tandem Diabetes Care, Veracyte and Xagenic. He has served as a founder, president and chairman of numerous venture stage companies. Prior to the formation of Domain, Jesse was vice president of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as president and CEO of Microsonics, a pioneer in computer image processing for cardiology. Previous to that, Jesse held executive positions at Technicon Instruments Corporation (now Siemens Medical Solutions Diagnostics) and at GE. He received his B.S. in physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University. | Quaker Partners manages venture capital and growth equity investments, with > $700 million-in-assets under management. Based in Philadelphia, PA. Quaker Partners has invested only in healthcare companies, primarily in the Mid-Atlantic Region. Sectors: Biopharmaceuticals, Medical Technology and Medical Devices, Clinical Diagnostics and Life Science Tools, Healthcare Services. Our funds are fully committed, and we are not making new investments at this time. | |
Other Seats | Regado Biosciences | Regado Biosciences | Regado Biosciences | Regado Biosciences |
Regado Biosciences Management Team
7 Team Members
Regado Biosciences has 7 executives. Regado Biosciences's founder is Doug Gooding. Regado Biosciences's current Chief Executive Officer, President is David J Mazzo.
Name | Work History | Title | Status |
|---|---|---|---|
Doug Gooding | Founder | Current | |
David J Mazzo | Chief Executive Officer, President | Current | |
Alexander R. Giaquinto | Senior Vice President | Current | |
Ellen McDonald | Senior Vice President | Current | |
Eli Gilboa | Founder | Former |
Name | Doug Gooding | David J Mazzo | Alexander R. Giaquinto | Ellen McDonald | Eli Gilboa |
|---|---|---|---|---|---|
Work History | |||||
Title | Founder | Chief Executive Officer, President | Senior Vice President | Senior Vice President | Founder |
Status | Current | Current | Current | Current | Former |
You May Also Like
Altair Therapeutics is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).
Alice Therapeutics is a biotechnology company.
DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's approach is based on the discovery of an innate IgM-mediated auto-immune pathway that is triggered by vascular injury in conditions such as diabetic nephropathy, sickle cell disease, and myocardial infarction. This pathway, dubbed N2, can initiate a cascade of tissue damaging events leading to loss of organ function.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.